Treatment for Mania

First-Line Monotherapy Options

• The American College of Cardiology is not applicable here, however, lithium remains the gold standard with the most robust long-term evidence, showing efficacy for acute mania with response rates of 38-62% and superior prophylaxis against both manic and depressive episodes 1
• Lithium should be initiated only in settings with personnel and facilities for close clinical and laboratory monitoring, including baseline complete blood count, thyroid function tests, urinalysis, BUN, creatinine, and serum calcium, as recommended by medical guidelines 2, 1
• The medical community recommends monitoring lithium levels, renal and thyroid function, and urinalysis every 3-6 months during maintenance therapy 1
• Lithium is FDA-approved for patients age 12 and older, according to the FDA 1
• Valproate demonstrates response rates of 53% in acute mania, superior to lithium (38%) in some pediatric studies, particularly effective for mixed or dysphoric mania, as per medical research 1
• Obtain baseline liver function tests, complete blood cell counts, and pregnancy test before initiating valproate, as advised by medical experts 2, 1
• The medical guidelines suggest monitoring serum drug levels, hepatic function, and hematological indices every 3-6 months for valproate 2, 1
• Avoid valproate in women of childbearing potential when possible due to teratogenic risk and association with polycystic ovary disease, as warned by medical authorities 1, 3
• Haloperidol or chlorpromazine should be routinely offered as first-line options in resource-limited settings, according to medical recommendations 2
• Second-generation antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone) are FDA-approved for acute mania in adults and provide more rapid symptom control than mood stabilizers alone, as approved by the FDA 1, 4
• Monitor body mass index monthly for 3 months then quarterly, and blood pressure, fasting glucose, and lipids at 3 months then yearly, as recommended by medical guidelines 1

Combination Therapy for Severe or Treatment-Resistant Mania

• Combination therapy with lithium or valproate plus an atypical antipsychotic represents a first-line approach for severe and treatment-resistant mania, as recommended by medical experts 1
• Quetiapine plus valproate is more effective than valproate alone for adolescent mania, according to medical research 1

Treatment Duration and Maintenance

• Continue antipsychotic treatment for at least 12 months after beginning of remission, as advised by medical guidelines 2
• Maintenance therapy with lithium or valproate should continue for at least 2 years after the last episode, with lithium showing superior evidence for long-term prophylaxis, as recommended by medical authorities 2, 1
• Withdrawal of maintenance lithium therapy dramatically increases relapse risk, with >90% of noncompliant adolescents relapsing versus 37.5% of compliant patients, as warned by medical experts 1
• Continue the regimen that effectively treated the acute episode for maintenance, as this approach maximizes long-term stability, according to medical guidelines 1

Adjunctive Treatments

• Anticholinergics should not be used routinely for preventing extrapyramidal side effects; reserve short-term use only for significant acute or severe symptoms when dose reduction and switching have failed, as recommended by medical experts 2
• Psychological treatments including relaxation therapy, cognitive behavioral therapy principles, psychoeducational programs, and family counseling may be considered as adjunctive treatment, according to medical research 2
• Psychoeducation and psychosocial interventions should accompany pharmacotherapy to improve outcomes, as advised by medical authorities 1

Critical Pitfalls to Avoid

• Never use antidepressant monotherapy in bipolar disorder, as this triggers manic episodes or rapid cycling, as warned by medical experts 1, 3
• Avoid unnecessary polypharmacy while recognizing that many patients require combination therapy for optimal control, according to medical guidelines 1
• Do not prematurely discontinue maintenance therapy, as inadequate duration leads to relapse rates exceeding 90%, as advised by medical authorities 1
• Conduct systematic medication trials with 6-8 week durations at adequate doses before concluding an agent is ineffective, as recommended by medical experts 1
• Monitor for metabolic side effects of atypical antipsychotics, particularly weight gain, diabetes risk, and dyslipidemia, according to medical guidelines 1